Equities

MiMedx Group Inc

MDXG:NAQ

MiMedx Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.53
  • Today's Change0.09 / 1.21%
  • Shares traded948.73k
  • 1 Year change+23.44%
  • Beta1.9086
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments826687
Total Receivables, Net544441
Total Inventory211311
Prepaid expenses5.628.656.15
Other current assets, total1.752.632.81
Total current assets164134149
Property, plant & equipment, net9.111114
Goodwill, net192020
Intangibles, net5.265.855.38
Long term investments------
Note receivable - long term------
Other long term assets0.210.150.19
Total assets239171188
LIABILITIES
Accounts payable9.058.857.39
Accrued expenses333435
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.05----
Other current liabilities, total2.700.440.36
Total current liabilities464442
Total long term debt484948
Total debt494948
Deferred income tax------
Minority interest------
Other liabilities, total2.224.774.87
Total liabilities969795
SHAREHOLDERS EQUITY
Common stock0.150.110.11
Additional paid-in capital276174166
Retained earnings (accumulated deficit)(134)(192)(162)
Treasury stock - common--0(4.02)
Unrealized gain (loss)------
Other equity, total------
Total equity1437593
Total liabilities & shareholders' equity239171188
Total common shares outstanding146114112
Treasury shares - common primary issue000.78
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.